Life Sciences

  • July 25, 2017

    Altor Bioscience Investors Fail To Halt $290M NantCell Merger

    Altor Bioscience Corp. investors lost a bid Tuesday for a temporary restraining order blocking the closing of Altor’s $290 million merger with billionaire physician Patrick Soon-Shiong’s NantCell Inc., with the Delaware Chancery Court finding there was no proof irreparable harm would follow.

  • July 25, 2017

    Shkreli Slams Katten Atty In Emails, As Trial Wraps Up

    Jurors in the securities fraud trial of Martin Shkreli on Tuesday heard from the last witness expected to be called in the case, and were shown a trove of emails showing the “pharma bro” berating his former Katten Muchin attorney and co-defendant as they discussed ways to pay off disgruntled investors.

  • July 25, 2017

    FDA Warning Wire: Cancer-Treating Claims On Christian Site

    The U.S. Food and Drug Administration expressed skepticism over claims on a religious website about vitamin supplements and cancer, scolded a water therapy device maker over its handling of customer complaints and cited sanitation worries at a compounding facility.

  • July 25, 2017

    Accutane Label Didn't Adequately Warn, NJ Panel Says

    The New Jersey Appellate Division on Tuesday upended court victories for Hoffman-La Roche Inc. and Roche Laboratories Inc. in hundreds of cases over the adverse affects of Accutane, ruling that the drug maker didn’t provide adequate warning in some cases and that a lower court wrongly applied New Jersey law in others.

  • July 25, 2017

    Celgene To Pay $280M To End Off-Label Cancer Drug FCA Suit

    Celgene Corp. has agreed to shell out $280 million to end a False Claims Act suit launched in California by a whistleblower who accused the drug company of promoting off-label uses for two cancer drugs, federal prosecutors announced on Tuesday.

  • July 25, 2017

    Pa. Appeals Court Asked To Lift Cap On Risperdal Damages

    The application of a New Jersey law limiting the availability of punitive damages against drugmakers unfairly curbed a Maryland man’s potential recovery from a Johnson & Johnson unit in a case over breast growth attributed to the antipsychotic drug Risperdal, a Pennsylvania appeals court heard during oral arguments on Tuesday.

  • July 25, 2017

    Olympus To Pay $6.6M Over Role In Patient's Deadly Infection

    A Washington state jury on Monday determined medical device maker Olympus Corp.’s medical scope wasn’t the cause of a patient's fatal infection in 2013, but ordered the company to pay about $6.6 million in damages to a Seattle hospital for failing to adequately instruct the hospital in how to properly use the device.

  • July 25, 2017

    Ex-Adviser Cops To Trading Scheme With Ex-Hunton Atty

    A former investment adviser admitted in Brooklyn federal court on Tuesday that he schemed to trade on inside information that a convicted ex-Hunton & Williams LLP attorney gleaned from a pharmaceutical industry client.

  • July 25, 2017

    BakerHostetler Nabs Thompson Hine Life Sciences Patent Atty

    BakerHostetler snagged a Thompson Hine LLP partner with extensive experience in intellectual property, health care and life sciences to work in its Cincinnati and Atlanta offices, the firm has announced.

  • July 25, 2017

    Paul Hastings Atty Joins Latham's White Collar Team

    Latham & Watkins LLP has hired a Paul Hastings LLP attorney and former federal prosecutor who's experienced in defending health care, life sciences and pharmaceutical companies against white collar criminal investigations, Latham said Tuesday.

  • July 25, 2017

    $5B Parexel Take-Private Deal Incites Investors

    Pamplona Capital Management LLP's plans to take biopharmaceutical services provider Parexel International Corp. private sparked a Massachusetts federal lawsuit Monday alleging the $5 billion deal is unfair to investors.

  • July 25, 2017

    Judge Reverses J&J's Win In Philly Pelvic Mesh Mass Tort

    A Pennsylvania state court judge has overturned part of a jury verdict that gave Johnson & Johnson its first win in five pelvic mesh trials in Philadelphia, ordering the company to face damages from allegations that an implant was defectively designed.

  • July 25, 2017

    GOP Narrowly Starts Debate On ACA Repeal

    Efforts to repeal the Affordable Care Act narrowly advanced in the U.S. Senate on Tuesday, as Republicans barely mustered enough votes to open debate on the deeply controversial legislation.

  • July 25, 2017

    Stada Boards Back Sweetened €4.12B Bain, Cinven Buyout

    German pharmaceutical company Stada Arzneimittel AG on Tuesday encouraged shareholders to accept a sweetened €4.12 billion ($4.8 billion) takeover offer from Bain Capital and Cinven, after an earlier buyout offer from the private equity shops failed to secure enough shareholder support to move forward.

  • July 25, 2017

    Holland & Knight Adds IP Attorney From Cantor Coburn

    Holland & Knight LLP has announced that it has strengthened its Atlanta office with a former Cantor Colburn LLP attorney who has 26 years of experience with intellectual property matters and serves clients in the pharmaceutical, biotechnology and medical device industries.

  • July 25, 2017

    Retailers Seek Docs Given To FTC In Aggrenox MDL

    Humana and retailers including Walgreen Co. and Rite Aid Corp. that are suing pharmaceutical companies over their alleged role in a scheme to block generic alternatives to stroke-prevention drug Aggrenox on Monday urged a Connecticut federal court to require the drugmakers to give them documents recently turned over to the Federal Trade Commission.

  • July 24, 2017

    SEC Wins Bid To Shield Notes From Atty Gone Fraudster

    A D.C. federal judge ruled Monday that an attorney convicted for his role in helping former NFL player Willie Gault manipulate a medical device company's stock can't use the Freedom of Information Act to pry most of the files he wants from the U.S. Securities and Exchange Commission.

  • July 24, 2017

    Democrats Launch New Campaign To Target Rx Drug Costs

    Democrats on Monday announced their plan to rein in drug prices through what they’re calling “A Better Deal,” which includes creating a new agency to handle price gouging, allowing Medicare to negotiate prices and making companies justify large price increases. 

  • July 24, 2017

    11 Teva Entities Can't Escape Pa. Generic Price-Fixing Suit

    A Pennsylvania federal judge ruled Monday that 11 generic pharmaceutical entities based outside the state still must face price-fixing allegations in a union health insurance plan’s putative class action, but she threw out claims against four drugmakers that do not sell drugs in the state, finding the court lacked jurisdiction.

  • July 24, 2017

    Dems Embark On Agenda To Limit Mergers, Tax Loopholes

    In an effort to turn around recent electoral losses, the Democratic party launched a campaign on Monday that attacks the Republicans’ tax reform goals as enriching the wealthy on the backs of those with lower incomes while promising to limit large mergers, rein in rising drug prices and boost wages.

Expert Analysis

  • Combating Securities Fraud Allegations With 10b5-1 Plans

    Yafit Cohn

    The recent case of Tetraphase Pharmaceuticals illustrates that 10b5-1 trading plans continue to provide a defense to insider trading allegations in securities fraud suits. Because some courts have begun to examine these plans more closely, however, there are a number of “best practices” to consider, say Yafit Cohn and Karen Hsu Kelley of Simpson Thacher & Bartlett LLP.

  • 5 Questions Firms Should Ask When Evaluating Litigation AFA

    Gregory Lantier

    Law firm management should understand the client’s reasons for requesting an alternative fee arrangement, and whether approving the fee will help grow the relationship with the client, say attorneys with WilmerHale.

  • For Law Firm Offices, Business Savvy Is The New Cool

    Craig Braham

    Having embraced the notion that the right space can reinforce the right firm culture, law firm leaders have been evaluating real estate primarily for its physical properties. However, it's hard to be collegial, even in the coolest of in-house coffee bars, if your cost structure is untenable, says Craig Braham of Advocate Commercial Real Estate Advisors LLC.

  • BPCIA Questions Continue To Arise For Biosimilar Applicants

    Christine Willgoos

    Whether and when an early notice of commercial marketing lifts the bar to declaratory judgment actions set forth in the Biologics Price Competition and Innovation Act is one of many issues likely to be litigated in the follow-up to the U.S. Supreme Court's decision in Sandoz v. Amgen, say attorneys with Kramer Levin Naftalis & Frankel LLP.

  • The Best Documents In Your Case May Be From 3rd Parties

    Wyatt Dowling

    Cases are built on evidence and evidence comes from discovery. But discovery is largely a voluntary process. Serving a document subpoena on a third party can be an efficient and creative way to fill in the gaps that may exist in the productions of opposing parties, says Wyatt Dowling of Yetter Coleman LLP.

  • Planning A Legal Career With A Future Relocation In Mind

    Jacqueline Bokser LeFebvre

    Lawyers move to New York City to work on some of the most sophisticated work the legal market has to offer. This exposure and experience is an amazing asset and many of the skills developed will make associates very marketable in the event they consider relocating to another market. However, this isn’t always the case, says Jacqueline Bokser LeFebvre of Major Lindsey & Africa.

  • 4 Female Perspectives On BigLaw Leadership

    Regina Pisa

    Only a handful of the largest U.S. law firms are led by women. Here, in their own words, are perspectives from Shook Hardy & Bacon Chair Madeleine McDonough, Crowell & Moring Chair Angela Styles, Morgan Lewis & Bockius Chair Jami Wintz McKeon and Goodwin Procter Chair Emeritus Regina Pisa.

  • The Elephant In The Room: Advancing Women To Partnership

    Anusia Gillespie

    Despite more focus and investment, the numbers continue to show little progress in advancing women to the top tiers of firm leadership. Considering the irreversible nature of the transformation of the market for top talent, it is time to start experimenting and innovating from the core, rather than from the periphery, say Anusia Gillespie and Scott Westfahl of Harvard Law School.

  • How Midsize Law Firms Can Minimize Cybersecurity Threats

    K. Stefan Chin

    It can be challenging for midsize law firms to develop an enterprise cybersecurity program that mitigates the eminent threat of data breach and meets the regulatory and compliance requirements of the firm and its clients. This challenge becomes daunting when considering the steady rise in client audits, say K. Stefan Chin of Peckar & Abramson PC and John Sweeney of Logicforce.

  • High Court Signals Interest In Vitamin C Price-Fix Case

    Nicholas Melzer

    For all companies engaged in international commerce, guidance from the U.S. Supreme Court on the Second Circuit's controversial decision in the Vitamin C Antitrust Litigation would be welcome. If the Supreme Court's recent request for input from the acting solicitor general is any indication, the court may agree, say Nicholas Melzer and Janet Chung of Holland & Knight LLP.